Your browser doesn't support javascript.
loading
Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group.
Gross, V; Andus, T; Ecker, K W; Raedler, A; Loeschke, K; Plauth, M; Rasenack, J; Weber, A; Gierend, M; Ewe, K; Schölmerich, J.
Affiliation
  • Gross V; Department of Internal Medicine I, University of Regensburg, Germany.
Gut ; 42(4): 493-6, 1998 Apr.
Article in En | MEDLINE | ID: mdl-9616309
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Crohn Disease / Budesonide / Anti-Inflammatory Agents Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Gut Year: 1998 Document type: Article Affiliation country: Alemania Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Crohn Disease / Budesonide / Anti-Inflammatory Agents Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Gut Year: 1998 Document type: Article Affiliation country: Alemania Country of publication: Reino Unido